MindShift #3 is live! In this issue: 🧪 Non-hallucinogenic psychedelics 🏛️ Why a former Texas governor backs ibogaine 🇨🇭 Swiss lessons on psychedelic-assisted therapy 🗞️ latest policy/markets/research updates Read: mindshift.news/p/mindshift-93… Subscribe: mindshift.news/subscribe

"Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability" sciencedirect.com/science/articl…

🤩What a nice surprise to see us mentioned by Jean Abbiateci, seasoned journalist and founder of the award-winning newsletter Bulletin. Curious? Read our latest issue: bit.ly/4oCg22F Want to support us? Subscribe (free, ad-free): mindshift.news/subscribe

Most psychedelics promote brain plasticity. But not all plasticity-promoting molecules are psychedelic! 👀✨ In our latest issue, meet tabernanthalog: it boosts neuroplasticity without hallucinations. A potential shortcut to safer therapies. 🔗 mindshift.news/p/mindshift-93…

It’s been a wild year for the psychedelic market: FDA’s Lykos rejection, RFK Jr.’s support, and AbbVie–Gilgamesh rumors have investors buzzing. Kabir Nath, CEO of Compass Pathways, reflects, and looks ahead. 🔗 mindshift.news/p/mindshift-93…

🎙️ New #DrugSciencePodcast: Education + ethics are essential in psychedelics. We speak with Sam Bloomfield & Dr. Eddie Jacobs about how to make access safer, fairer & smarter. drugscience.org.uk/podcast

Our CEO & Co-Founder, Cosmo Feilding Mellen, joined Labiotech.eu’s Beyond Biotech podcast to discuss how next-gen psychedelics could help patients with treatment-resistant depression. Listen here podcast.labiotech.eu/1995493/episod… #MentalHealth #Psychedelics #Biotech

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) globenewswire.com/news-release/2…

x.com/psyched_alpha/…

While the U.S. 🇺🇸 rolls out psychedelics in a fragmented way, Switzerland 🇨🇭 has offered regulated psychedelic therapy for decades, treating 1,600+ patients. In our last issue, we asked: what can the U.S. learn? 🔗 mindshift.news/p/mindshift-93…

The Johns Hopkins Center for Psychedelic and Consciousness Research is committed to public education. Join us for Understanding Psychedelic Experiences with Dr. David Yaden at Profs and Pints in Baltimore, MD. 📅 Tue, Aug 19 at 6 PM 📍 The Perch, 1110 S Charles St 🎟️ $13.50 adv |

What could turn a 75-year-old conservative into one of psychedelics’ most avid champions? Rick Perry’s unexpected journey started with one ibogaine experience. Full story in our last issue: 🔗 mindshift.news/p/mindshift-93…

️Biomedical research has a male bias, and psychedelic science is no exception. Even animal studies often exclude females. In our last issue, we covered two studies showing how sex shapes psychedelic effects, cautioning against this bias. ♀️♂ 🔗 mindshift.news/p/mindshift-93…

In our last issue: Psychedelics are at the center of America’s church-state debate. Should religious freedom protect their use? 🍄✝️⚖️ A Utah judge just set a precedent, siding with a faith group use of shrooms against Utah county. #psychedelic #ReligiousFreedom #MentalHealth

Our fourth issue is here! In this edition: 💊 Striping the mind naked down to pure awareness. 👁️ Seeing with the mind for the first time. 💰 $1.2 billion industry milestone. 🗞️The latest news on legalization, markets, and research. Read the full issue: lnkd.in/evQMmATM

True! #MentalHealth can’t wait. As countries shape better policies and care, it’s worth asking: should #psychedelics be part of the conversation?